BTIG Research Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock

Verastem (NASDAQ:VSTM) had its price target hoisted by stock analysts at BTIG Research from $18.00 to $24.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s price objective indicates a potential upside of 211.28% from the company’s current price.

Several other research firms have also weighed in on VSTM. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $19.00 target price on shares of Verastem in a report on Thursday. Guggenheim set a $12.00 target price on shares of Verastem and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of Verastem from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 4th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Verastem in a research report on Monday, October 5th. Finally, Citigroup reaffirmed a “buy” rating on shares of Verastem in a report on Thursday, October 8th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Verastem Stock Up 3.5%

Verastem stock opened at $7.71 on Thursday. The business’s 50-day moving average price is $7.54 and its 200 day moving average price is $5.91. The company has a quick ratio of 2.22, a current ratio of 2.25 and a debt-to-equity ratio of 1.48. The firm has a market cap of $698.22 million, a price-to-earnings ratio of -2.90 and a beta of 0.39. Verastem has a 52 week low of $3.43 and a 52 week high of $10.82.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Verastem had a negative return on equity of 467.49% and a negative net margin of 231.59%. The company had revenue of $40.08 million during the quarter, compared to the consensus estimate of $22.88 million. As a group, sell-side analysts anticipate that Verastem will post -1.55 earnings per share for the current year.

Insider Buying and Selling at Verastem

In other news, CEO Dan Paterson sold 44,121 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $8.00, for a total transaction of $352,968.00. Following the completion of the transaction, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at $5,221,696. This represents a 6.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 48,044 shares of company stock worth $381,484. Corporate insiders own 1.94% of the company’s stock.

Institutional Investors Weigh In On Verastem

Several institutional investors and hedge funds have recently added to or reduced their stakes in VSTM. Armistice Capital LLC raised its position in Verastem by 68.7% during the fourth quarter. Armistice Capital LLC now owns 3,536,000 shares of the biopharmaceutical company’s stock worth $27,298,000 after acquiring an additional 1,440,000 shares during the period. AIGH Capital Management LLC purchased a new position in Verastem during the first quarter valued at $10,600,000. Opaleye Management Inc. acquired a new stake in shares of Verastem in the second quarter valued at about $6,876,000. Exome Asset Management LLC grew its position in shares of Verastem by 58.5% in the first quarter. Exome Asset Management LLC now owns 636,700 shares of the biopharmaceutical company’s stock valued at $3,375,000 after purchasing an additional 234,957 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Verastem by 31.6% during the first quarter. Bank of America Corp DE now owns 416,985 shares of the biopharmaceutical company’s stock worth $2,210,000 after purchasing an additional 100,123 shares in the last quarter. Hedge funds and other institutional investors own 88.37% of the company’s stock.

More Verastem News

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Promising cancer-treatment data: VS-7375 demonstrated anti-tumor activity in advanced KRAS G12D-mutated pancreatic, lung and colorectal cancers. The company reported a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma, including two complete responses in second-line-or-later disease, with favorable safety and tolerability. VS-7375 clinical data
• Positive Sentiment: Path toward Phase III: The results strengthen the investment case for VS-7375 and support Verastem’s preparation for pivotal, late-stage testing. Positive results in multiple tumor types could expand the drug’s commercial opportunity if confirmed in larger trials. Verastem Phase III plans
• Positive Sentiment: Substantial funding secured: Verastem priced an underwritten offering expected to raise approximately $250 million, consisting of 30.94 million common shares at $8.00 each and pre-funded warrants. The proceeds should provide important capital for clinical development and reduce near-term financing risk. Verastem offering
• Positive Sentiment: Leadership succession announced: Michael P. Bailey will become president and CEO on January 1, 2027, when Daniel Paterson retires. The planned transition may provide continuity while the company advances VS-7375 into later-stage development. CEO succession announcement
• Neutral Sentiment: Trading in VSTM was briefly halted under a limit-up/limit-down pause, reflecting unusually active trading and volatility surrounding the announcements.
• Negative Sentiment: The equity financing will materially increase the share count, creating dilution for existing holders. Investors must also weigh the risks that early clinical results may not be replicated in Phase III trials or lead to regulatory approval.

About Verastem

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.